The purpose of the study was to examine the association of plasma lipid concentrations with changes in cognitive function and depressive states in elderly Greek individuals. The study population consisted of 3 groups: A) 37 subjects with dementia, B) 33 subjects with depression, and C) 33 controls. All individuals were screened with the Mini-Mental State Examination (MMSE), the Geriatric Depression Scale (GDS), and an evaluation of their psychiatric state. Lipid profile was assessed in all subjects, and the results were statistically evaluated at P < .05 level of significance. Groups A and B had significantly lower levels of total plasma cholesterol and HDL cholesterol than group C (P < .01). Triglyceride levels did not differ significantly between groups A and C, although they were significantly higher in group B. The results of this study suggest that an association does exist between the plasma concentration of cholesterol and HDL-C and depression and/or cognitive impairment. Further studies are required to explore the significance of these observations and establish if lipid levels could serve as markers for diagnostic and therapeutic purposes. (J Geriatr Psychiatry Neurol 2007;20:138-144)
Hofman A., Rocca WA, Brayne C.The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings . Int J Epidemiol. 1991;20:736-748.
2.
Ritchie K., Kildea D.Is senile dementia age-related ar ageing-related? Evidence from a meta-analysis of dementia prevalence in the oldest-old. Lancet. 1995;346:931-934.
3.
Skoog I., Nilsson L., Palmertz B., Andreasson LA, Svanborg A.A population-based study of dementia in 85-year-olds. N Eng J Med.1993;328:153-158.
4.
Jorm A., Korten AE, Henderson ASThe prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand.1987;76:465-479.
5.
Lebowitz B., Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA.1997;278:1186-1190.
6.
Doody R., Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2001;56:1154-1166.
7.
Hofman A., Ott A., Breteler Mmb, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet. 1997;349:151-154.
8.
Kivipelto M. , Helkala EL, Hanninen T., et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. Neurology. 2001;56:1683-1689.
9.
Simons M., Keller P., Dichgans J., Schulz JBCholesterol and Alzheimer's disease. Is there a link?Neurology . 2001;57: 1089-1093.
10.
Tan Z., Seshadri S., Beiser A., et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med.2003;163:1053-1057.
11.
Caramelli P. , Nitrini R., Maranhao R., et al. Increase apolipoprotin B serum concentration in Alzheimer's disease. Acta Neurol Scand.1999;100:61-63.
12.
Moroney J., Tang MX, Berglund L., et al. Low-Density Lipoprotein Cholesterol and the Risk of Dementia with Stroke. JAMA.1999;282:254-260.
13.
Morgan R., Palinkas LA, Barret-Connel EL, Wingard DLPlasma cholesterol and depressive symptoms in older men. Lancet. 1993;341:75-79.
14.
Aijanseppa S., Kivinen P., Helkala EL, Kivela SL, Tuomilehto J., Nissinen A.Serum cholesterol and depressive symptoms in elderly Finnish men. Int J Geriatr Psychiatry. 2002;17: 629-634.
15.
Stewart R., Sharples KJ, North FM, Menkes DB, Baker J., Simes J.Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators . Arch Intern Med.2000;160:3144-3152.
16.
Ergun U., Uguz S., Bozdemir N., et al. The relationship between cholesterol levels and depression in the elderly. Int J Geriatr Psychiatry. 2004 ;19:291-296.
17.
Vertesi A., Lever JA, Molloy DW, et al. Standardized mini-mental state examination; use and interpretation . Can Fam Phys. 2001;47:2018-2023.
18.
Sajatovic M., Ramirez L.Geriatric Depression Scale (GDS). In: Sajatovic M, Ramirez L, ed. Rating Scales in Mental Health. Hudson, Oh: Lexi-Comp, Inc.; 2003:405-406.
19.
Rapp S., Walsh DA, Parisi SA, Wallace CEDetecting depression in elderly medical inpatients. J Consult Clin Psychol.1998;56:509-513.
20.
Iliffe S., Haines A., Gallivan S., Booroff A., Goldenberg E., Morgan P.Assessment of elderly people in general practice. Br J Gen Pract.1991;41:9-15.
21.
Blazer D.Depression in the elderly: myths and misconceptions. Psychiatr Clin North Am. 1997;20:111-119.
22.
Gorelick P.Risk factors for vascular dementia and Alzheimer's disease. Stroke. 2004;35:2620-2622.
23.
Stern Y., Alexander GE, Prohovnik I., Mayeux R.Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol.1992;32:371-375.
24.
Evans R., Emsley MS, Gao S., et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: A population-based study of African Americans. Neurology. 2000;54:240.
25.
Pappolla M. , Bryant-Thomas TK, Herbert D., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199-205.
26.
Henderson V. , Guthrie JR, Dennerstein L.Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry . 2003;74:1530-1535.
27.
Schalk B., Visser M., Deeg DJ, Bouter LMLower levels of serum albumin and total cholesterol and future decline in functional performance in older persons: the Longitudinal Aging Study Amsterdam . Age Ageing.2004;33:266-272.
28.
Zuliani G., Ble A., Zanca R., et al. Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease. BMC Geriatr. 2001 ;1:5.
29.
van Exel E. , de Craen AJ, Gussekloo J., et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol.2002;51:716-721.
30.
Reitz C., Tang MX, Luchsinger J., Mayeux R.Relation of plasma lipids to Alzheimer's disease and vascular dementia. Arch Neurol.2004;61:705-714.
31.
Dietschy J. , Turley SDCholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12:105-112.
32.
Brown S., Salive ME, Harris TB, Simonsick EM, Guralnik JM, Kohout FJLow cholesterol concentrations and severe depressive symptoms in elderly people . Br Med J.1994;308:1328-1332.
33.
Partonen T. , Haukka J., Virtamo J., Taylor PR, Lonnqvist J.Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry. 1999;175:259-262.
34.
Terao T., Iwata N., Kanazawa K., et al. Low serum cholesterol levels and depressive state in human dock visitors. Acta Psychiatr Scand.2000;101:231-234.
35.
Nakao M., Yano E.Relationship between major depression and high serum cholesterol in Japanese men. Tohoku J Exp Med.2004;204:273-287.
36.
Alexopoulos G., Meyers BS, Young RC, Kakuma T., Silbersweig D., Charlson M.Clinically defined vascular depression. Am J Psychiatry.1997;154:562-565.
37.
Krishnan K. , Hays JC, Blazer DGMRI-defined vascular depression. Am J Psychiatry.1997;154:497-501.
38.
Casserly I. , Topol E.Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139-1146.
39.
Ritchie K., Lovestone S.The dementias. Lancet. 2002;360: 1759-1766.
40.
Wolozin B., Kellman W., Ruosseau P., Celesia GG, Siegel G.Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol.2000;57:1439-1443.
41.
Pappolla M. , Bryant-Thomas TK, Herbert D., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology.2003;61: 199-205.
42.
Refolo L., Pappolla MA, Malester B., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
43.
Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003 ;24:637-643.
44.
Porter FDRSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab. 2000;71:163-174.
45.
Greeve I., Hermans-Borgmeyer I., Brellinger C., et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci.2000;20:7345-7352.
46.
Ledesma MD, Abad-Rodriguez J., Galvan C., et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep.2003;4:1190-1196.
47.
Abad-Rodriguez J., Ledesma MD, Craessaerts K., et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol.2004:6;167:809-812.
48.
Ledesma MD, Dotti CGThe conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp. 2005;72:129-138.
49.
Strittmatter W., Roses ADApolipoprotein E and Alzheimer's disease. Annu Rev Neurosci.1996;19:53-77.
